Literature DB >> 16184247

[Visceral obesity, hypertension and cardio-renal risk: a review].

Eduardo Cantoni Rosa1, Maria Teresa Zanella, Artur Beltrame Ribeiro, Osvaldo Kohlmann Junior.   

Abstract

Great part of obesity adversity is due to its cardiovascular/coronary risk, particularly present in obese with visceral adiposity distribution. Visceral fat deposition is known to be associated with a greater prevalence of metabolic, neurohormonal, inflammatory and hemodynamic disorders, which together will be implicated in microvascular and target organ involvement, particularly to the cardio-renal axis. In this aspect, beyond its classical association with coronary disease, visceral obesity has been associated with left ventricular hypertrophy and microalbuminuria, which are known cardiac and nephrologic risk factors. So, therapeutic tools for obese patients, specially for those with hypertension, must accomplish the risk stratification based on body fat distribution, which will allow a more adequate therapy in terms of risk factors control as well as target organ damage monitoring.

Entities:  

Mesh:

Year:  2005        PMID: 16184247     DOI: 10.1590/s0004-27302005000200005

Source DB:  PubMed          Journal:  Arq Bras Endocrinol Metabol        ISSN: 0004-2730


  3 in total

1.  Improvement of thoracic aortic vasoreactivity by continuous and intermittent exercise in high-fat diet-induced obese rats.

Authors:  Hongpeng Liu; Zhen Yang; Jian Hu; Yan Luo; Lingqin Zhu; Huifang Yang; Guanghua Li
Journal:  Biomed Rep       Date:  2015-04-16

2.  Ischemia heart disease and greater waist circumference are risk factors of renal function deterioration in male gout patients.

Authors:  Ben Yu-Jih Su; Han-Ming Lai; Chung-Jen Chen; Ying-Chou Chen; Chun-Kai Chiu; Ko-Ming Lin; Shan-Fu Yu; Tien-Tsai Cheng
Journal:  Clin Rheumatol       Date:  2007-11-20       Impact factor: 2.980

3.  Intermittent exercise improves the vasoreactivity of the thoracic aorta in rats.

Authors:  Tao Xu; Yan Luo; Shuting Hu; Ling Hou; Jianguo Niu; Guanghua Li
Journal:  Biomed Rep       Date:  2016-02-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.